LuciRepo

Description

COMPOSITION:

Each LuciRepo capsule contains: Repotrectinib ………………………….…… 40mg

INDICATION:

LuciRepo is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

DOSAGE AND USE:

• Select patients for the treatment of locally advanced or metastatic NSCLC based on the presence of ROS1 rearrangement(s) in tumor specimens.

• Recommended Dosage: 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food.

Capsules should be swallowed whole & not chewed or crushed.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciRepo during Pregnancy and Lactation.